News from juventas therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 16, 2015, 08:05 ET Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy

Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to...

May 12, 2015, 09:10 ET Juventas Therapeutics Adds $13.5 Million In New Financing And Expands Board Of Directors

Juventas Therapeutics, Inc., a clinical-stage biotechnology company focused on developing non-viral gene therapies to treat advanced cardiovascular...

Nov 18, 2014, 09:10 ET Juventas Therapeutics Presents Phase II Data at AHA Scientific Sessions That Shows JVS-100 is Safe, Potentially Effective in Patients with Critical Limb Ischemia

Juventas Therapeutics Inc., a privately-held, clinical-stage company developing novel therapies for treatment of cardiovascular disease, had clinical ...

Nov 12, 2014, 09:10 ET Juventas Therapeutics Phase II Clinical Study Results to be Presented at 2014 American Heart Association Scientific Sessions

Juventas Therapeutics Inc., a privately-held, clinical-stage company developing novel therapies for treatment of cardiovascular disease, today...

Oct 28, 2014, 09:10 ET Juventas Therapeutics Strengthens Management Team with New Senior Vice President of Finance and Operations

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease...

Aug 12, 2014, 09:05 ET Juventas Therapeutics completes enrollment of Phase I/II RETRO-HF trial and demonstrates safety for retrograde infusion of JVS-100 in patients with heart failure

Juventas Therapeutics, Inc., a private clinical-stage company developing a drug-based approach to regenerative medicine today announced that it...

Jul 23, 2014, 10:11 ET Juventas Therapeutics strengthens leadership team by adding two industry veterans

Juventas Therapeutics, a clinical-stage biotechnology company developing a first-in-class regenerative gene therapy for treatment of heart failure...

Dec 09, 2013, 09:35 ET Juventas Therapeutics initiates first clinical trial for retrograde infusion of a gene therapy to patients with heart failure

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease,...

Oct 28, 2013, 09:00 ET Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel therapies for treatment of cardiovascular disease, announced today...

Jan 28, 2013, 09:00 ET Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease...

Aug 20, 2012, 09:00 ET Juventas Therapeutics doses first patient in Phase II STOP-HF trial

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease,...

Jul 16, 2012, 09:00 ET Juventas Therapeutics Raises $22.2 Million Series B Financing

Juventas Therapeutics, a clinical-stage regenerative medicine company, announced today that it has closed a $22.2 million Series B financing that was ...

May 15, 2012, 09:00 ET Juventas Therapeutics Enrolling Patients in Phase IIa STOP-CLI Clinical Trial

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is...

Jan 30, 2012, 09:00 ET Juventas Therapeutics Reports One Year Data From Phase I Heart Failure Clinical Trial

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease....

Apr 26, 2011, 08:00 ET Juventas Therapeutics Completes Successful Phase I Clinical Trial for JVS-100 in Treatment of Patients with Heart Failure

Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that it has...

Apr 05, 2010, 08:00 ET Juventas Therapeutics Enrolling Phase I Clinical Trial of JVS-100 for Patients with Heart Failure

Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I...